PT  - JOURNAL ARTICLE
AU  - Faverio, Paola
AU  - Luppi, Fabrizio
AU  - Rebora, Paola
AU  - Busnelli, Sara
AU  - Stainer, Anna
AU  - Catalano, Martina
AU  - Parachini, Luca
AU  - Monzani, Anna
AU  - Galimberti, Stefania
AU  - Bini, Francesco
AU  - Bodini, Bruno Dino
AU  - Betti, Monia
AU  - Giacomi, Federica De
AU  - Scarpazza, Paolo
AU  - Oggionni, Elisa
AU  - Scartabellati, Alessandro
AU  - Bilucaglia, Luca
AU  - Ceruti, Paolo
AU  - Modina, Denise
AU  - Harari, Sergio
AU  - Caminati, Antonella
AU  - Valsecchi, Maria Grazia
AU  - Bellani, Giacomo
AU  - Foti, Giuseppe
AU  - Pesci, Alberto
TI  - Six-month pulmonary impairment after severe COVID-19: a prospective, multicenter follow-up study
AID  - 10.1101/2021.03.29.21254151
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.03.29.21254151
4099  - http://medrxiv.org/content/early/2021/03/30/2021.03.29.21254151.short
4100  - http://medrxiv.org/content/early/2021/03/30/2021.03.29.21254151.full
AB  - Background and objective Long-term pulmonary sequelae following SARS-CoV-2 pneumonia are not yet confirmed, however preliminary observations suggests a possible relevant clinical, functional and radiological impairment. The aim of this study was to identify and characterise pulmonary sequelae caused by SARS-CoV-2 pneumonia at 6-month follow-up.Methods In this multicenter, prospective, observational cohort study, patients hospitalised for SARS-CoV-2 pneumonia and without prior diagnosis of structural lung diseases were stratified by maximum ventilatory support (“oxygen only”, “continuous positive airway pressure (CPAP)” and “invasive mechanical ventilation (IMV)”) and followed up at 6 months from discharge. Pulmonary function tests and diffusion capacity for carbon monoxide (DLCO), 6 minutes walking test, chest X-ray, physical exam and modified Medical Research Council (mMRC) dyspnoea score were collected.Results Between March and June 2020, 312 patients were enrolled (83, 27% women; median [IQR] age 61.1 [53.4,69.3] years). The parameters that showed the highest rate of impairment were DLCO and chest-X-ray, in 46% and 25% of patients, respectively. However, only a minority of patients reported dyspnoea (31%), defined as mMRC ≥ 1, or showed a restrictive ventilatory defects (9%). In the logistic regression model, having asthma as comorbidity was associated with DLCO impairment at follow-up, while prophylactic heparin administration during hospitalisation appeared as a protective factor. Need for invasive ventilatory support during hospitalisation was associated with chest imaging abnormalities.Conclusion DLCO and radiological assessment appear to be the most sensitive tools to monitor patients with COVID-19 during follow-up. Future studies with longer follow-up are warranted to better understand pulmonary sequelae.Summary at a glance DLCO and radiological assessment are the most sensitive tools to monitor COVID-19 patients at 6-month follow-up. Invasive ventilatory support is a risk factor for detection of radiological abnormalities, but not for DLCO impairment, at follow-up. Whileuse of prophylactic heparin acts as a protective factor on the development of DLCOimpairment.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04435327Funding StatementThe authors have no funding to declare.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study received Ethics Committee approval (ASST Monza, 3389, May 21st 2020)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesIndividual participant data referring to this article (i.e. text, tables and figures) will be made available upon reasonable request. The study protocol will be made available for researchers who provide a methodologically sound proposal. Proposals should be directed to paola.faverio{at}unimib.it